Chimerix to Present at TD Cowen 44th Annual Health Care Conference
27 Février 2024 - 1:00PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
announced that Mike Andriole, Chief Executive Officer, will
participate in a Targeted Oncology Panel at the TD Cowen 44th
Annual Health Care Conference on Tuesday, March 5, 2024 at 12:50
p.m. ET.
An audio webcast of the panel discussion will be available on
the Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
CONTACT: Will
O’ConnorStern Investor Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Chimerix (NASDAQ:CMRX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
